Welcome to NanoViricide's Investor Relations section.
NanoViricides, Inc. is a leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology permits direct attacks at multiple points on a virus particle. It is believed that such actions lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody.
We have been aggressively expanding our portfolio of virus targets and drug candidates every year since our inception in May, 2005.
"PENICILLIN" FOR VIRUSES
Eradicating Diseases Caused by Viruses Using 21st Century Nanotechnology
Presented by: Eugene Seymour, MD, MPH
Chief Executive Officer
December - 2017
November 26, 2018 - NanoViricides Files Quarterly Report for Period Ending September 30, 2018
October 29, 2018 - NanoViricides, Inc. Appoints Mr. James Sapirstein to its Board of Directors
October 22, 2018 - NanoViricides CEO Dr. Irach Taraporewala Presents a Letter to Shareholders
- 04-15-2014 NanoViricides won the IAIR AWARD
- NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
- 02-20-2014Dr. Anil R. Diwan Recognized as "Researcher of the year".
- NanoViricides, Inc. President Dr. Anil R. Diwan Recognized as "Researcher of the Year" by BusinessNewHaven, a Connecticut Area Business Journal.
1 Controls Drive,
Shelton, CT 06484